JPH0570604B2 - - Google Patents
Info
- Publication number
- JPH0570604B2 JPH0570604B2 JP60028142A JP2814285A JPH0570604B2 JP H0570604 B2 JPH0570604 B2 JP H0570604B2 JP 60028142 A JP60028142 A JP 60028142A JP 2814285 A JP2814285 A JP 2814285A JP H0570604 B2 JPH0570604 B2 JP H0570604B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- carbon atoms
- group
- alkyl
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 cephem compounds Chemical class 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 230000004043 responsiveness Effects 0.000 claims abstract description 3
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 4
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 20
- 210000002540 macrophage Anatomy 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- BOFUZZAQNVYZFF-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-methylmorpholine Chemical compound CC1NCCOC1C1=CC=CC(Cl)=C1 BOFUZZAQNVYZFF-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯äººéããã³åç©ã®å
ç«ç³»ã調ç¯ããã
ãã®ã次åŒã§ç€ºãããã»ããšã ååç©ãæå¹é
å«æããçµæç©ã«é¢ããã
ãã®ã次åŒã§ç€ºãããã»ããšã ååç©ãæå¹é
å«æããçµæç©ã«é¢ããã
ãåã
ãåŒäžãR1ã¯æ°ŽçŽ ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ã«ãã«ãã«ã«ããã·ã¡ãã«ïŒãã
ã§ã該ã«ã«ããã·ã«åºã¯ççåŠçã«å容ã§ããå¡©
ãŸãã¯ççåŠçã«å容ã§ãããšã¹ãã«ã®åœ¢ãããŠ
ããŠãããïŒãã¢ã«ã³ãã·ã«ã«ããã«ã¡ãã«ãã¢
ããã«ã«ããã«ã¡ãã«ãŸãã¯ã·ã¢ãã¡ãã«ã§ã
ãããŸãããããã®åºäžã®ã¡ãã¬ã³åºã¯å Žåã«ã
ã眮æãããŠããŠãããïŒ R2ã¯æ°ŽçŽ ãççåŠçã«å容ã§ããã«ããªã³ãŸ
ãã¯ççåŠçã«å容ã§ãããšã¹ãã«åºã§ããïŒ R3ã¯ããããã·ã«ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠ
ããããšãããã¢ã«ã±ã³ãªãã·ãã¢ã«ãã³ãªã
ã·ãã·ã¯ãã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ãªãŒã«ãªãã·ãå Žåã«ãã眮æã
ããŠããããšãããã¢ã©ã«ã³ãã·ãã¢ãããã¢ã«
ãã«ã¢ããããžã¢ã«ãã«ã¢ããïŒããã§ããã®äº
åã®ã¢ã«ãã«åºã¯éç°ããŠïŒãïŒå¡ç°ã圢æãã
ããšãã§ãã該ç°ã¯ãŸãå Žåã«ããå¥ã®ããçŽ ãŸ
ãã¯é žçŽ ååãå«æããŠããŠãããïŒãã¢ã«ã±ã
ã«ã¢ããããŸãã¯å Žåã«ãã眮æãããŠããããš
ãããã¢ãªãŒã«ã¢ããè¥ããã¯ã¢ãªãŒã«âCH2â
ã¢ããã§ããïŒ R1åºã¯ã·ã³äœçœ®ã«é 眮ããŠãããã 眮æåºR1ïŒR2ããã³R3ã«ã€ããŠæŽã«è©³çŽ°ã«èª¬
æããã R1ãâå Žåã«ãã眮æãããŠããããšããã
ã¢ã«ãã«âã瀺ãå Žåãç¹ã«å¥œé©ãªã¢ã«ãã«ã¯ç
çŽ ååãïŒåãïŒåæãããã®ãäŸãã°ãã¡ã
ã«ããšãã«ãïœâãããã«ãã€ãœãããã«ãïœâ
ããã«ããã³ã€ãœããã«ãªã©ã§ãããç¹ã«å¥œãŸã
ããã®ã¯ã¡ãã«ã§ããããããã®ã¢ã«ãã«åºã¯ïŒ
å以äžïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºãç¹ã«ããã²
ã³ïŒå¥œãŸããã¯å¡©çŽ ãŸãã¯èçŽ ïŒãããããã·ã«
ãŸãã¯ã¹ã«ãã«ãã眮æããããšãã§ããã奜ãŸ
ãã眮æã¢ã«ãã«åºã¯äŸãã°ïŒâã¯ãããšãã«ã
ãã³ïŒâããã¢ãšãã«ã§ããã R1ãâå Žåã«ãã眮æãããŠããããšããã
ã¢ã«ã³ãã·ã«ã«ããã«ã¡ãã«âã瀺ãå Žåããã®
å ŽåããŸã奜ãŸããåºã¯ççŽ ååãïŒãïŒåæã
ãã¢ã«ãã«éšåãå«æããŠãããç¹ã«å¥œãŸããã
ã®ã¯ã¡ããã·ã«ã«ããã«ã¡ãã«ããã³ãšããã·ã«
ã«ããã«ã¡ãã«ã§ããã R1ãã«ã«ããã·ã¡ãã«ïŒè©²ã«ã«ããã·ã«åºã¯
ãŸãççåŠçã«å容ã§ããå¡©ãŸãã¯ççåŠçã«å
容ã§ãããšã¹ãã«ã®åœ¢ã§ããããšãã§ããïŒãã¢
ã«ã³ãã·ã«ã«ããã«ã¡ãã«ãã¢ããã«ã«ããã«ã¡
ãã«ããã³ã·ã¢ãã¡ãã«ã§ããå Žåããããã®åº
ããã®åºäžã®ã¡ãã¬ã³åºãäŸãã°ççŽ ååãïŒã
ïŒåæããã¢ã«ãã«ïŒå¥œãŸããã¯ã¡ãã«ïŒã«ãã€
ãŠïŒåãŸãã¯ïŒå眮æãããŠããŠããããïŒå眮
æãããŠããå ŽåãïŒåã®ã¢ã«ãã«çœ®æåºãéç°
ããŠãç¹ã«ïŒãïŒå¡ïŒå¥œãŸããã¯ïŒãïŒå¡ïŒã®ç
çŽ ç°åŒåºã圢æããããšãã§ããããã®ãããªå
容ã«ãããã奜ãŸããåºã¯äŸãã°ãã«ã«ããã·ã¡
ãã«ãïŒâã«ã«ããã·ãšãã«ãïŒâã«ã«ããã·ãš
ãã«ãïŒâã«ã«ããã·ã€ãœãããã«ãã¡ããã·ã«
ã«ããã«ã¡ãã«ããšããã·ã«ã«ããã«ã¡ãã«ãã¢
ããã«ã«ããã«ã¡ãã«ããã³ã·ã¢ãã¡ãã«ãªã©ã
ãããããã R1ãæ°ŽçŽ ã瀺ãååç©ãæ¬çºæã«ãšã€ãŠå¥œãŸ
ããååç©ã§ããã R2ãççåŠçã«å容ã§ãããšã¹ãã«åºã瀺ã
å Žåã奜é©äŸã¯ïŒâã¢ã·ã«ãªãã·ã¢ã«ãã«ã§ã
ããã¢ã·ã«ããã³ã¢ã«ãã«éšåã®äž¡æ¹ãšãççŽ å
åãïŒãïŒåã奜ãŸããã¯ïŒãïŒåæãããäŸã
ã°ãã¢ã»ããã·ã¡ãã«ãïŒâã¢ã»ããã·ãšãã«ã
ïŒâã¢ã»ããã·ãããã«ãïŒâã¢ã»ããã·ã€ãœã
ããã«ãïŒâã¢ã»ããã·ããã·ã«ãããããªãã«
ãªãã·ã¡ãã«ãïŒâããããªãã«ãªãã·ãšãã«ã
ïŒâããããªãã«ãªãã·ãããã«ãïŒâããããª
ãã«ãªãã·ããã·ã«ãïŒâãããã€ã«ãªãã·ã¡ã
ã«ãããã³ïŒâãããã€ã«ãªãã·ãšãã«ãªã©ã§ã
ããç¹ã«ã¢ã»ããã·ã¡ãã«ãïŒâã¢ã»ããã·ãšã
ã«ãïŒâããããªãã«ãªãã·ãšãã«ããã³ããã
ã€ã«ãªãã·ã¡ãã«ã§ããã ç¹ã«å¥œãŸããR2ã¯ççåŠçæ¡ä»¶äžã§é€å»ãã
ããšã®ã§ãããšã¹ãã«åºãäŸãã°
ãããšãããã¢ã«ãã«ãã«ã«ããã·ã¡ãã«ïŒãã
ã§ã該ã«ã«ããã·ã«åºã¯ççåŠçã«å容ã§ããå¡©
ãŸãã¯ççåŠçã«å容ã§ãããšã¹ãã«ã®åœ¢ãããŠ
ããŠãããïŒãã¢ã«ã³ãã·ã«ã«ããã«ã¡ãã«ãã¢
ããã«ã«ããã«ã¡ãã«ãŸãã¯ã·ã¢ãã¡ãã«ã§ã
ãããŸãããããã®åºäžã®ã¡ãã¬ã³åºã¯å Žåã«ã
ã眮æãããŠããŠãããïŒ R2ã¯æ°ŽçŽ ãççåŠçã«å容ã§ããã«ããªã³ãŸ
ãã¯ççåŠçã«å容ã§ãããšã¹ãã«åºã§ããïŒ R3ã¯ããããã·ã«ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠ
ããããšãããã¢ã«ã±ã³ãªãã·ãã¢ã«ãã³ãªã
ã·ãã·ã¯ãã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ãªãŒã«ãªãã·ãå Žåã«ãã眮æã
ããŠããããšãããã¢ã©ã«ã³ãã·ãã¢ãããã¢ã«
ãã«ã¢ããããžã¢ã«ãã«ã¢ããïŒããã§ããã®äº
åã®ã¢ã«ãã«åºã¯éç°ããŠïŒãïŒå¡ç°ã圢æãã
ããšãã§ãã該ç°ã¯ãŸãå Žåã«ããå¥ã®ããçŽ ãŸ
ãã¯é žçŽ ååãå«æããŠããŠãããïŒãã¢ã«ã±ã
ã«ã¢ããããŸãã¯å Žåã«ãã眮æãããŠããããš
ãããã¢ãªãŒã«ã¢ããè¥ããã¯ã¢ãªãŒã«âCH2â
ã¢ããã§ããïŒ R1åºã¯ã·ã³äœçœ®ã«é 眮ããŠãããã 眮æåºR1ïŒR2ããã³R3ã«ã€ããŠæŽã«è©³çŽ°ã«èª¬
æããã R1ãâå Žåã«ãã眮æãããŠããããšããã
ã¢ã«ãã«âã瀺ãå Žåãç¹ã«å¥œé©ãªã¢ã«ãã«ã¯ç
çŽ ååãïŒåãïŒåæãããã®ãäŸãã°ãã¡ã
ã«ããšãã«ãïœâãããã«ãã€ãœãããã«ãïœâ
ããã«ããã³ã€ãœããã«ãªã©ã§ãããç¹ã«å¥œãŸã
ããã®ã¯ã¡ãã«ã§ããããããã®ã¢ã«ãã«åºã¯ïŒ
å以äžïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºãç¹ã«ããã²
ã³ïŒå¥œãŸããã¯å¡©çŽ ãŸãã¯èçŽ ïŒãããããã·ã«
ãŸãã¯ã¹ã«ãã«ãã眮æããããšãã§ããã奜ãŸ
ãã眮æã¢ã«ãã«åºã¯äŸãã°ïŒâã¯ãããšãã«ã
ãã³ïŒâããã¢ãšãã«ã§ããã R1ãâå Žåã«ãã眮æãããŠããããšããã
ã¢ã«ã³ãã·ã«ã«ããã«ã¡ãã«âã瀺ãå Žåããã®
å ŽåããŸã奜ãŸããåºã¯ççŽ ååãïŒãïŒåæã
ãã¢ã«ãã«éšåãå«æããŠãããç¹ã«å¥œãŸããã
ã®ã¯ã¡ããã·ã«ã«ããã«ã¡ãã«ããã³ãšããã·ã«
ã«ããã«ã¡ãã«ã§ããã R1ãã«ã«ããã·ã¡ãã«ïŒè©²ã«ã«ããã·ã«åºã¯
ãŸãççåŠçã«å容ã§ããå¡©ãŸãã¯ççåŠçã«å
容ã§ãããšã¹ãã«ã®åœ¢ã§ããããšãã§ããïŒãã¢
ã«ã³ãã·ã«ã«ããã«ã¡ãã«ãã¢ããã«ã«ããã«ã¡
ãã«ããã³ã·ã¢ãã¡ãã«ã§ããå Žåããããã®åº
ããã®åºäžã®ã¡ãã¬ã³åºãäŸãã°ççŽ ååãïŒã
ïŒåæããã¢ã«ãã«ïŒå¥œãŸããã¯ã¡ãã«ïŒã«ãã€
ãŠïŒåãŸãã¯ïŒå眮æãããŠããŠããããïŒå眮
æãããŠããå ŽåãïŒåã®ã¢ã«ãã«çœ®æåºãéç°
ããŠãç¹ã«ïŒãïŒå¡ïŒå¥œãŸããã¯ïŒãïŒå¡ïŒã®ç
çŽ ç°åŒåºã圢æããããšãã§ããããã®ãããªå
容ã«ãããã奜ãŸããåºã¯äŸãã°ãã«ã«ããã·ã¡
ãã«ãïŒâã«ã«ããã·ãšãã«ãïŒâã«ã«ããã·ãš
ãã«ãïŒâã«ã«ããã·ã€ãœãããã«ãã¡ããã·ã«
ã«ããã«ã¡ãã«ããšããã·ã«ã«ããã«ã¡ãã«ãã¢
ããã«ã«ããã«ã¡ãã«ããã³ã·ã¢ãã¡ãã«ãªã©ã
ãããããã R1ãæ°ŽçŽ ã瀺ãååç©ãæ¬çºæã«ãšã€ãŠå¥œãŸ
ããååç©ã§ããã R2ãççåŠçã«å容ã§ãããšã¹ãã«åºã瀺ã
å Žåã奜é©äŸã¯ïŒâã¢ã·ã«ãªãã·ã¢ã«ãã«ã§ã
ããã¢ã·ã«ããã³ã¢ã«ãã«éšåã®äž¡æ¹ãšãççŽ å
åãïŒãïŒåã奜ãŸããã¯ïŒãïŒåæãããäŸã
ã°ãã¢ã»ããã·ã¡ãã«ãïŒâã¢ã»ããã·ãšãã«ã
ïŒâã¢ã»ããã·ãããã«ãïŒâã¢ã»ããã·ã€ãœã
ããã«ãïŒâã¢ã»ããã·ããã·ã«ãããããªãã«
ãªãã·ã¡ãã«ãïŒâããããªãã«ãªãã·ãšãã«ã
ïŒâããããªãã«ãªãã·ãããã«ãïŒâããããª
ãã«ãªãã·ããã·ã«ãïŒâãããã€ã«ãªãã·ã¡ã
ã«ãããã³ïŒâãããã€ã«ãªãã·ãšãã«ãªã©ã§ã
ããç¹ã«ã¢ã»ããã·ã¡ãã«ãïŒâã¢ã»ããã·ãšã
ã«ãïŒâããããªãã«ãªãã·ãšãã«ããã³ããã
ã€ã«ãªãã·ã¡ãã«ã§ããã ç¹ã«å¥œãŸããR2ã¯ççåŠçæ¡ä»¶äžã§é€å»ãã
ããšã®ã§ãããšã¹ãã«åºãäŸãã°
ãåŒã
ãåŒããªã©ã§ããã
R2ãšããŠäœ¿çšãããççåŠçã«å容ã§ããã«
ããªã³ã¯äŸãã°ãã¢ãªã«ãªéå±ã€ãªã³ïŒç¹ã«ãã
ãªãŠã ããã³ã«ãªãŠã ã€ãªã³ïŒãã¢ã«ã«ãªåé¡é
å±ã€ãªã³ïŒç¹ã«ãã«ã«ã·ãŠã ããã³ãã°ãã·ãŠã
ã€ãªã³ïŒãããã³ã¢ã³ã¢ããŠã ã€ãªã³ãªã©ã§ããã
奜ãŸããã«ããªã³ã¯ãããªãŠã ã€ãªã³ããã³å Žå
ã«ãã眮æãããŠããããšãããã¢ã«ãã«åã¢ã³
ã¢ããŠã ã€ãªã³ïŒããã§ã該ã¢ã«ãã«åºïŒåã¯ç
çŽ ååãïŒãïŒåæããããšãã§ããïŒãäŸãã°ã
ããªãšãã«ã¢ã³ã¢ããŠã ããžãšãã«ã¢ã³ã¢ããŠ
ã ããžã¡ãã«ã¢ã³ã¢ããŠã ãŸãã¯ã¢ãªããªããŠã
ãªãã³ã«ãããã³åããã圢ã®ããªãžã³ãŸãã¯ã¢
ã«ã®ãã³ã®ãããªå¡©åºæ§ã¢ããé žãªã©ã§ããã åèšã®ççåŠçã«å容ã§ããã«ããªã³ããã³ãš
ã¹ãã«ã¯R1ãã«ã«ããã·ã¢ã«ãã«åºã®å¡©ãŸãã¯
ãšã¹ãã«ã®åœ¢ãããåºã§ããå Žåã«ã€ããŠã奜é©
ã§ããã R3ã¯äŸãã°æ¬¡ã®(a)ã(l)ã®åºã§ããã (a) ããããã·ã«ïŒ (b) ã¢ã«ã³ãã·ïŒççŽ ååãïŒãïŒåã奜ãŸãã
ã¯ãïŒãïŒåæãããïŒè©²ã¢ã«ã³ãã·ã¯ïŒåãŸ
ãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºã§çœ®æã
ãããšãã§ããã眮æåºã¯äŸãã°ãããããã·
ã«ãããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ããã³èçŽ ïŒã
ã«ã«ããã·ã«ãã¢ããã«ã«ããã«ãã¢ã«ã³ãã·
ïŒççŽ ååãïŒãïŒåæããïŒãã¢ã«ã³ãã·ã¢ã«
ã³ãã·ïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒå
æããïŒãã¢ã«ã³ãã·ã¢ã«ã³ãã·ã¢ã«ã³ãã·
ïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæã
ãïŒãã¢ãªãŒã«ãŸãã¯ã¢ãªãŒã«ãªãã·ïŒç¹ã«ã
ãšãã«ãŸãã¯ããšãã«ãªãã·ãããã§ã該ã¢ãª
ãŒã«ã¯å Žåã«ãããããããã·ã«ãC1ãC4ã¢
ã«ãã«ãC1ãC4ã¢ã«ã³ãã·ãããã²ã³ïŒç¹ã«
å¡©çŽ ããã³èçŽ ïŒãã«ã«ããã·ã«ãã¢ã«ã³ãã·
ã«ã«ããã«ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåæããïŒãŸãã¯ã¢ããã«ã«ããã«ã«ããïŒ
åãŸãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒçœ®æãããŠã
ãããšãããïŒãªã©ã§ããïŒ (c) ã¢ã«ã±ã³ãªãã·ïŒççŽ ååãïŒãïŒåã奜ãŸ
ããã¯ïŒãïŒåæãããïŒè©²ã¢ã«ã±ã³ãªãã·ã¯
ããšãã«ã§ïŒåãŸãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒ
眮æããããšãã§ããããŸã眮æåºã®ããšãã«
ãããããã·ã«ãC1ãC4ã¢ã«ãã«ãC1ãC4ã¢
ã«ã³ãã·ãããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ããã³è
çŽ ïŒãã«ã«ããã·ã«ãã¢ã«ã³ãã·ã«ã«ããã«
ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæããïŒ
ãŸãã¯ã¢ããã«ã«ããã«ã«ããïŒåãŸãã¯æ°å
ïŒå¥œãŸããã¯ïŒåïŒçœ®æãããŠããŠãããïŒ (d) ã¢ã«ãã³ãªãã·ïŒççŽ ååãïŒãïŒåã奜ãŸ
ããã¯ïŒãïŒåæãããïŒïŒ (e) ã·ã¯ãã¢ã«ã³ãã·ïŒççŽ ååãïŒãïŒåã奜
ãŸããã¯ïŒãïŒåæãããïŒïŒ (f) ã¢ãªãŒã«ãªãã·ïŒå¥œãŸããã¯ãããšãã«ãªã
ã·ãïŒè©²ã¢ãªãŒã«ãªãã·ã¯å Žåã«ããïŒåãŸã
ã¯æ°åïŒå¥œãŸããã¯ïŒåãŸãã¯ïŒåïŒã®çœ®æåº
ã§çœ®æããããšãã§ããã眮æåºã¯ããã²ã³
ïŒç¹ã«å¡©çŽ ããã³èçŽ ïŒãC1ãC4ã¢ã«ãã«ãã
ãããã·ã«ãC1ãC4ã¢ã«ã³ãã·ãããããã¢
ãããC1ãC4ã¢ã«ãã«ã¢ããããžã¢ã«ãã«ã¢
ããïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæ
ããïŒãã¹ã«ããã¢ããã«ã«ããã«ãã«ã«ãã
ã·ã«ãŸãã¯ã¢ã«ã³ãã·ã«ã«ããã«ïŒè©²ã¢ã«ãã«
éšåã¯ççŽ ååãïŒãïŒåæããïŒã§ããïŒ (g) ã¢ã©ã«ã³ãã·ïŒå¥œãŸããã¯ããšãã«ã¢ã«ã³ã
ã·ãããã§ã該ã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåã奜ãŸããã¯ïŒãïŒåæãããïŒè©²ã¢ã©ã«
ã³ãã·åºã®ã¢ãªãŒã«éšåã¯å Žåã«ããïŒåãŸã
ã¯æ°åã奜ãŸããã¯ãïŒåãŸãã¯ïŒåã®çœ®æåº
ã§çœ®æããããšãã§ããã該眮æåºã¯ããã²ã³
ïŒå¥œãŸããã¯å¡©çŽ ããã³èçŽ ïŒãC1ãC4ã¢ã«ã
ã«ãããããã·ã«ãC1ãC4ã¢ã«ã³ãã·ããã
ããã¢ãããC1ãC4ã¢ã«ãã«ã¢ããããžã¢ã«
ãã«ã¢ããïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåæããïŒãã¹ã«ããã«ã«ããã·ã«ãã¢ã«ã³
ãã·ã«ã«ããã«ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååã
ïŒãïŒåæããïŒãŸãã¯ã¢ããã«ã«ããã«ã§ã
ãïŒ (h) ã¢ããïŒ (i) ã¢ã«ãã«ã¢ããïŒè©²ã¢ã«ãã«éšåã¯ççŽ åå
ãïŒãïŒåæããïŒïŒ (j) ãžã¢ã«ãã«ã¢ããïŒåã¢ã«ãã«éšåã¯ççŽ å
åãïŒãïŒåæããããŸãã該ã¢ã«ãã«éšåã¯
éç°ããŠïŒãïŒå¡ã奜ãŸããã¯ãïŒãïŒå¡ç°ã
圢æããããšãã§ãããŸãã該ç°ã¯å Žåã«ãã
å¥ã®ããçŽ ååãŸãã¯é žçŽ ååãå«æããããš
ãã§ããïŒïŒ (k) ã¢ã«ã±ãã«ã¢ããïŒè©²ã¢ã«ã±ãã«éšåã¯ççŽ
ååãïŒãïŒåã奜ãŸããã¯ãïŒãïŒåæã
ãïŒïŒ (l) ã¢ãªãŒã«ã¢ãããŸãã¯ã¢ãªãŒã«ã¡ãã«ã¢ãã
ïŒç¹ã«ãããšãã«ã¢ãããŸãã¯ãã³ãžã«ã¢ããïŒ
該ã¢ãªãŒã«éšåã¯å Žåã«ããïŒåãŸãã¯æ°å
ïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºã§çœ®æãããŠããŠ
ãããã該眮æåºã¯ããã²ã³ïŒç¹ã«å¡©çŽ ãŸãã¯
èçŽ ïŒãC1ãC4ã¢ã«ãã«ãããããã·ãC1ãC4
ã¢ã«ã³ãã·ãããããã¢ãããC1ãC4ã¢ã«ã
ã«ã«ããããžã¢ã«ãã«ã¢ããïŒåã¢ã«ãã«éšå
ã¯ççŽ ååãïŒãïŒåæããïŒããŸãã¯ã¢ãã
ã«ã«ããã«ã§ããïŒ ãªã©ã§ããã æ¬çºæã«ãšã€ãŠç¹ã«å¥œãŸããR3ã®åºãäžèšã«
ãããã R3ãççŽ ååãïŒãïŒåæããå Žåã«ãã眮
æãããŠããããšãããã¢ã«ã³ãã·åºã瀺ãå Ž
åãå ·äœäŸãšããŠã¯ã¡ããã·ããšããã·ãããã
ãã·ãã€ãœããããã·ããããã·ãã€ãœããã
ã·ãïœâãããã·ãã¡ããã·ãšããã·ããšããã·
ãšããã·ãã¡ããã·ãšããã·ãšããã·ãã¡ããã·
ãšããã·ãšããã·ãšããã·ããšããã·ãšããã·ãš
ããã·ãšããã·ãããšããã·ãšããã·ãïŒâã¯ã
ãããšããã·ãšããã·ãïŒâã¡ãã«ããšããã·ãš
ããã·ããã³ïŒâã¡ããã·ããšããã·ãšããã·ãª
ã©ãããããããã¡ããã·ããšããã·ãã€ãœãã
ããã·ãã€ãœãããã·ãïœâãããã·ãã¡ããã·
ãšããã·ãã¡ããã·ãšããã·ãšããã·ãããšãã
ã·ãšããã·ããã³ïŒâã¯ããããšããã·ãç¹ã«å¥œ
ãŸããã R3ãå Žåã«ãã眮æãããŠããããšãããã¢
ã«ã±ã³ãªãã·ã瀺ãå Žåãå ·äœäŸãšããŠã¯ã¢ãªã«
ãªãã·ããã³ã·ã³ããã«ãªãã·ãç¹ã«å¥œãŸããåº
ãšããŠãããããã R3ãã¢ã«ãã³ãªãã·ã§ããå Žåãç¹ã«å¥œãŸã
ããã®ã¯ãããã«ã®ã«ãªãã·ã§ããã R3ãã·ã¯ãã¢ã«ã³ãã·ã§ããå Žåãããã¯äŸ
ãã°ãã·ã¯ãããããã·ãã·ã¯ããããã·ãã·ã¯
ããã³ãã«ãªãã·ãŸãã¯ã·ã¯ãããã·ã«ãªãã·ãª
ã©ã§ãããã·ã¯ããã³ãã«ãªãã·ããã³ã·ã¯ãã
ãã·ã«ãªãã·ãç¹ã«å¥œãŸããã R3ãã¢ãªãŒã«ãªãã·ã瀺ãå ŽåãR3ã¯ããšã
ãã·ãïŒâããªã«ãªãã·ãïŒâã¯ããããã³ïŒâ
ã¯ããããšããã·ãïŒïŒïŒâãžã¯ããããšãã
ã·ãïŒâããããã·ããã³ïŒâããããã·ããšã
ãã·ãïŒïŒïŒâãžããããã·ããšããã·ãïŒâã¡
ããã·ããšããã·ãïŒïŒïŒâãžã¡ããã·ããšãã
ã·ãïŒâãããããšããã·ãïŒâãããããšãã
ã·ãïŒâã¢ããããšããã·ãïŒâãžã¡ãã«ã¢ãã
ããšããã·ãïŒâãžãšãã«ã¢ããããšããã·ãïŒ
âã¹ã«ãããšããã·ãïŒâã«ã«ããã·ããšãã
ã·ãïŒâã«ã«ããã·ããšããã·ãïŒâãšããã·ã«
ã«ããã«ããšããã·ããã³ïŒâã¢ããã«ã«ããã«
ããšããã·ãªã©ã§ãããããšããã·ãïŒâã¯ãã
ããšããã·ãïŒïŒïŒâãžã¯ããããšããã·ãïŒâ
ã¡ããã·ããšããã·ãïŒïŒïŒâãžã¡ããã·ããšã
ãã·ãããã³ïŒâãžã¡ãã«ã¢ãããã·ãç¹ã«å¥œãŸ
ããã R3ãã¢ã©ã«ã³ãã·ã瀺ãå ŽåãäŸãã°ããã³
ãžã«ãªãã·ãïŒâã¡ãã«ãã³ãžã«ãªãã·ãïŒâã¯
ãããã³ãžã«ãªãã·ãïŒâã¡ããã·ãã³ãžã«ãªã
ã·ãïŒïŒïŒâãžã¡ããã·ãã³ãžã«ãªãã·ãïŒâã
ãããã·ãã³ãžã«ãªãã·ãïŒâããããã³ãžã«ãª
ãã·ãïŒâã«ã«ããã·ãã³ãžã«ãªãã·ãïŒâã«ã«
ããã·ãã³ãžã«ãªãã·ãïŒâãšããã·ã«ã«ããã«
ãã³ãžã«ãªãã·ãïŒâã¢ããã«ã«ããã«ãã³ãžã«
ãªãã·ãïŒâãžã¡ãã«ã¢ãããã³ãžã«ãªãã·ãã
ã³ããšãããã·ãªã©ããããããã奜ãŸããåºã¯
ãã³ãžã«ãªãã·ãïŒâã¯ãããã³ãžã«ãªãã·ã
ïŒïŒïŒâãžã¯ãããã³ãžã«ãªãã·ãïŒâã¡ããã·
ãã³ãžã«ãªãã·ãïŒïŒïŒâãžã¡ããã·ãã³ãžã«ãª
ãã·ãïŒâã«ã«ããã·ãã³ãžã«ãªãã·ãïŒâã¢ã
ããã³ãžã«ãªãã·ããã³ïŒâãžã¡ãã«ã¢ãããã³
ãžã«ãªãã·ã§ããã R3ãã¢ã«ãã«ã¢ããã§ããå Žåãããã¯äŸã
ã°ãã¡ãã«ã¢ããããšãã«ã¢ããããããã«ã¢ã
ããŸãã¯ããã«ã¢ããã瀺ãããšãã§ããã奜ãŸ
ããã¯ã¡ãã«ã¢ããããã³ãšãã«ã¢ããã瀺ãã R3ããžã¢ã«ãã«ã¢ããã瀺ãå Žåãããã¯äŸ
ãã°ããžã¡ãã«ã¢ããããžãšãã«ã¢ããããžãã
ãã«ã¢ããããžã€ãœãããã«ã¢ãããïŒâãããª
ãžã«ãïŒâãããªãžãã«ãïŒâããã©ãžãã«ãïŒ
âãšãã«âïŒâããã©ãžãã«ãããã³ïŒâã¢ã«ã
ãªãã«ãªã©ã§ããã奜ãŸããã¯ããžã¡ãã«ã¢ã
ãããžãšãã«ã¢ãããïŒâãããªãžã«ãïŒâãã
ãªãžãã«ããã³ïŒâã¢ã«ããªãã«ã§ããã R3ãã¢ã«ã±ãã«ã¢ããã瀺ãå Žåãå ·äœäŸãš
ããŠãã¢ãªã«ã¢ããããããããã R3ãã¢ãªãŒã«ã¢ããã§ããå Žåãå ·äœäŸã«ã¯ã
ã¢ããªããïŒâããªã«ã¢ãããïŒâã¯ããããšã
ã«ã¢ãããïŒâããããã·ããšãã«ã¢ãããïŒâ
ã¡ããã·ããšãã«ã¢ãããïŒâã¡ããã·ããšãã«
ã¢ãããïŒâãããããšãã«ã¢ãããïŒâã¢ãã
ããšãã«ã¢ãããïŒâã¡ãã«ã¢ããããšãã«ã¢ã
ããïŒâãžã¡ãã«ã¢ããããšãã«ã¢ãããïŒâã¹
ã«ãããšãã«ã¢ãããïŒâã«ã«ããã·ããšãã«ã¢
ãããïŒâã«ã«ããã·ããšãã«ã¢ãããïŒâãšã
ãã·ã«ã«ããã«ããšãã«ã¢ãããããã³ïŒâã¢ã
ãã«ã«ããã«ããšãã«ã¢ãããªã©ããããããã
奜ãŸããåºã¯ã¢ããªããïŒâã¯ããããšãã«ã¢ã
ããïŒâã¡ããã·ããšãã«ã¢ãããïŒâã«ã«ãã
ã·ããšãã«ã¢ãããããã³ïŒâã¢ããã«ã«ããã«
ããšãã«ã¢ããã§ããã察å¿ãã眮æåºã¯ã¢ãªãŒ
ã«âCH2âã¢ããåºã«ã奜é©ã§ããã æ¬çºæã«ãããŠäœ¿çšããã®ã«ç¹ã«å¥œãŸããåå
ç©ã¯ã»ããªãžãžã ïŒcefodizimïŒã§ãããããã¯
åŒäžã®R1ãã¡ãã«ã§ãããR2ãNaã瀺ãããã
ãŠR3ãONaã瀺ãäžè¬åŒã®ååç©ã«çžåœããã äžè¬åŒã®ååç©ããã³ãã®è£œé æ¹æ³ã¯äŸã
ã°ã西ç¬ç¹èš±å ¬éå ¬å ±ç¬¬2716707å·ãå第3117438
å·ããã³å第3143537å·ã«é瀺ãããŠããã çç©ãäœæ¶²ããã³çŽ°èå ç«é²åŸ¡æ©æ§ãæããã
ãšã¯å ¬ç¥ã§ããããã®å ç«é²åŸ¡æ©æ§ã¯ãäœå ã«æµž
å ¥ãããããŠçºç å€åãèµ·ããããšã®ããç°ç©ã
äžåããã³é€å»ãããå ç«ç³»ã®é害ã«ãšããªã
ãããŸãã¯ãäŸãã°åŸ®çç©ãŸãã¯ç现èã®ãããª
ç åäœãæ±ãå ç«æ©èœã®äžå šã«èµ·å ããæ§ã ãªçŸ
æ£ãããããã®ãããæã ã¯çäœã®é²åŸ¡æ©æ§ãæ¯
æŽããã®ã«åºç¯ã«äœ¿çšã§ããé«å¹çã§é«èš±å®¹æ§ã®
å ç«èª¿æŽç©è³ªãé·å¹Žã«ããããããæ±ããŠããã æ¬çºæã®ç®çã¯ãå ç«è¬çåŠç掻æ§ãæããç§
åŠçã«ç»å®ãããäœæ¯æ§ã§ãããããå±æããã³
å šèº«æ§çŽ°èææã®æ²»ççšã®çŸçšæçç©è³ªã§ããæ°
ããã¿ã€ãã®ç©è³ªãæäŸããããšã§ãããäŸã
ã°ãã¯ãã©ã ããšãã³ãŒã«ãŸãã¯ããã©ãµã€ã¯ãª
ã³ã®ãããªããããæèäœçšãæããå€ãã®åå
ç©ã¯çäœã®é²åŸ¡æ©æ§ã«å¯ŸããŠå¯äœçšãæããããš
ãç¥ãããŠãããåŸã€ãŠãæ¬çºæã«ããååç©ã
äœæ¿åºŠã§å ç«å¿çã«å¯ŸããŠæçãªå¹æãæããã
å³ã¡ããã®ãããªååç©ã¯æ害ãªå¯äœçšãªãã«å
ç«å¿çæ§ãé«ããããšãã§ããããšããããšã¯ã
ã©ããã¹ãããšã§ãã€ãã åŸã€ãŠãæ¬çºæã®æ°èŠååç©ã¯åºç¯å²ã¹ãã¯ã
ã«ã®æçç©è³ªãšããŠå¥œé©ã§ããã°ããã§ãªããã
ã®å ç«åºæ¿äœçšã«ãã第ïŒã®éèŠãªæ©èœãçºæ®ã
ãããã®ããšã¯çãŸãã€ãããŸãã¯å 倩çã«äœè
æ§ã®æ£è ãéŠå°Ÿããå埩ãããã®ã«æ¥µããŠéèŠã§
ãããæŽã«ãæ¬çºæã®æ°èŠååç©ã¯ææçã®äºé²
ãŸãã¯åŸ®çç©ã®é€å»ãããã¯çäœãã现èãå€æ§
ãããããã«ã䜿çšã§ãããäŸãã°ãåç©è©Šéšã«
ãããŠãã»ããªãžãžã ãäºé²æäžããããšã«ãã€
ãŠããŠã¹ã®èŽæ»æ§ã®ã«ã³ãžãææçã«å¯Ÿãã芳å¯
æéã®æçµæ¥ïŒ14æ¥ç®ïŒã§65ïŒ ä»¥äžã®çåçãåŸ
ããããšããç»æçå¹æã確èªããããåã芳å¯
æéã«ã€ããŠè¡ãªãããå¯Ÿç §çŸ€ã§ã¯å¯ã®äžå¹ã®ã
ãŠã¹ãçåããªãã€ãã æ¬çºæã«ããã°ã掻æ§æåã¯éçµå£ããã³çµå£
ã®ãããã®çµè·¯ã«ãã€ãŠãæäžã§ããã å ç«èª¿ç¯äœçšãæããæäžéã¯ãéçµå£æäžã®
å ŽåãäœéïŒKgãããïŒã200mgã奜ãŸããã¯10
ã50mgã®ç¯å²å ã§ããã掻æ§æåã¯åç¬ã§æäžã
ãããšãã§ãããããããã¯ãææçããã³çè «
çã«å¯ŸããŠææãªå¹æãæãããã®ä»ã®è¬å€ãšäœµ
çšããŠæäžããããšãã§ããã氎溶液ã®è£œå€ã®å Ž
åã掻æ§æåã¯å¥œãŸããã¯ãäŸãã°åèšã®R2ã®
å®çŸ©ããæãããªããã«ã氎溶æ§ã§ãããããç
çåŠçã«å容ãããå¡©ã®åœ¢ã§äœ¿çšãããåŠæ¹ã«ã¯
åžžçšã®å©å€ããã³ããã¯ã«ãé åã§ããããã®ã
ããªå©å€ããã³ããã¯ã«ãšããŠå¥œé©ãªãã®ã¯äŸã
ã°å¢éå€ãä¹³åå€ãæ»æ²¢å€ãããã³ç·©è¡åå€ã§ã
ãã掻æ§æåã¯éé¢é žãŸãã¯å¡©ãšããŠè£œå€çšå©å€
ãšæ··åããããéé¢é žã®åœ¢ã§æ··åããå Žåãé©åœ
ãªå¡©åºãçéã ãå©å€ã«æ·»å ãã¹ãã§ãããã掻
æ§æåãæžæ¿æ¶²ã®åœ¢ã§äœ¿çšãããå Žåã補å€çšã«
䜿çšã§ãã奜é©ãªããã¯ã«ã¯äŸãã°æ€ç©æ²¹ã®ãã
ãªããããã·ã«åºãå«æããªã溶å€ã§ããã äžèšã«ç€ºãããå®éšçµæã¯äžè¬åŒã®ååç©ã®
å ç«èª¿ç¯äœçšãäŸèšŒãããã®ã§ãããå ç«èª¿ç¯äœ
çšãè©äŸ¡ããã®ã«å¥œé©ã§ããããšãç¥ãããŠãã
æ§ã ãªè©Šéšæ¹æ³ã䜿çšããã å®æœäŸ ïŒ ããŠã¹ã®è ¹èãã¯ããã¢ãŒãžã®åºæ¿ ãã¯ããã¢ãŒãžã¯ææçã«å¯Ÿããæµæããã³å
ç«å¿çã«ãããŠäžå¿ç圹å²ãæŒãããäžæ¹ã§ã¯ã
ãã¯ããã¢ãŒãžèªäœãç åäœãæé€ããä»æ¹ã§
ã¯ããã¯ããã¢ãŒãžã¯äœæ¶²ïŒïŒ¢â现èäŸåæ§ïŒå
ç«å¿çããã³çŽ°èïŒïŒŽâ现èäŸåæ§ïŒå ç«å¿çã®
調ç¯ã«ãããã³ã³ãããŒã«æ©èœãæããã ã»ããªãžãžã ã7.5ã60mgïŒKgïŒããŠã¹ïŒã®é
ã®æ§ã ãªæ¿åºŠã§NMRIããŠã¹ã«é泚ïŒïŒåïŒã
ããè¬å€ãæäžããŠãã72æéåŸãè ¹èãã¯ãã
ã¢ãŒãžãåé¢ãããããŠãåæ©èœã«ã€ããŠè©Šéšã
ããå¯Ÿç §çŸ€ããåé¢ãããã¯ããã¢ãŒãžãšæ¯èŒã
ããšãã»ããªãžãžã ïŒ15ã60mgïŒKgïŒããŠã¹ïŒïŒ
ã§åŠçããããŠã¹ããåé¢ãããã¯ããã¢ãŒãžã®
ååŠã«ãããã»ã³ã¹åå¿ã¯æäžéã®å¢å ã«ã€ããŠ
èããå¢å€§ããïŒè¡šïŒïŒã ã»ããªãžãžã ïŒåŒãåŒäžR1ïŒCH3ïŒR2ïŒ
NaïŒR3ïŒONaïŒã§åŠçããããŠã¹ããåé¢ãã
ãã¯ããã¢ãŒãžã¯ãªãœãœãŒã é µçŽ ã®å«éãå¢å€§ã
ãããšã«ãã€ãŠãåºå¥ãããã ã»ããªãžãžã ã§åŠçãããããŠã¹ããåé¢ãã
ãã¯ããã¢ãŒãžã«ããã³ãã€ãç¶éïŒ198AuïŒã®
飲äœçšã¯éåŠçããŠã¹ããåé¢ãããã¯ããã¢ãŒ
ãžã«æ¯ã¹ãŠãé¡èã«å¢å€§ããïŒå¯Ÿç §çŸ€ã§ã¯0.207
Ã103cpmãªã®ã«å¯ŸããŠã»ããªãžãžã ã§åŠçãã
ããŠã¹ããåé¢ãããã¯ããã¢ãŒãžã§ã¯0.43Ã
103ïŒã
ããªã³ã¯äŸãã°ãã¢ãªã«ãªéå±ã€ãªã³ïŒç¹ã«ãã
ãªãŠã ããã³ã«ãªãŠã ã€ãªã³ïŒãã¢ã«ã«ãªåé¡é
å±ã€ãªã³ïŒç¹ã«ãã«ã«ã·ãŠã ããã³ãã°ãã·ãŠã
ã€ãªã³ïŒãããã³ã¢ã³ã¢ããŠã ã€ãªã³ãªã©ã§ããã
奜ãŸããã«ããªã³ã¯ãããªãŠã ã€ãªã³ããã³å Žå
ã«ãã眮æãããŠããããšãããã¢ã«ãã«åã¢ã³
ã¢ããŠã ã€ãªã³ïŒããã§ã該ã¢ã«ãã«åºïŒåã¯ç
çŽ ååãïŒãïŒåæããããšãã§ããïŒãäŸãã°ã
ããªãšãã«ã¢ã³ã¢ããŠã ããžãšãã«ã¢ã³ã¢ããŠ
ã ããžã¡ãã«ã¢ã³ã¢ããŠã ãŸãã¯ã¢ãªããªããŠã
ãªãã³ã«ãããã³åããã圢ã®ããªãžã³ãŸãã¯ã¢
ã«ã®ãã³ã®ãããªå¡©åºæ§ã¢ããé žãªã©ã§ããã åèšã®ççåŠçã«å容ã§ããã«ããªã³ããã³ãš
ã¹ãã«ã¯R1ãã«ã«ããã·ã¢ã«ãã«åºã®å¡©ãŸãã¯
ãšã¹ãã«ã®åœ¢ãããåºã§ããå Žåã«ã€ããŠã奜é©
ã§ããã R3ã¯äŸãã°æ¬¡ã®(a)ã(l)ã®åºã§ããã (a) ããããã·ã«ïŒ (b) ã¢ã«ã³ãã·ïŒççŽ ååãïŒãïŒåã奜ãŸãã
ã¯ãïŒãïŒåæãããïŒè©²ã¢ã«ã³ãã·ã¯ïŒåãŸ
ãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºã§çœ®æã
ãããšãã§ããã眮æåºã¯äŸãã°ãããããã·
ã«ãããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ããã³èçŽ ïŒã
ã«ã«ããã·ã«ãã¢ããã«ã«ããã«ãã¢ã«ã³ãã·
ïŒççŽ ååãïŒãïŒåæããïŒãã¢ã«ã³ãã·ã¢ã«
ã³ãã·ïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒå
æããïŒãã¢ã«ã³ãã·ã¢ã«ã³ãã·ã¢ã«ã³ãã·
ïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæã
ãïŒãã¢ãªãŒã«ãŸãã¯ã¢ãªãŒã«ãªãã·ïŒç¹ã«ã
ãšãã«ãŸãã¯ããšãã«ãªãã·ãããã§ã該ã¢ãª
ãŒã«ã¯å Žåã«ãããããããã·ã«ãC1ãC4ã¢
ã«ãã«ãC1ãC4ã¢ã«ã³ãã·ãããã²ã³ïŒç¹ã«
å¡©çŽ ããã³èçŽ ïŒãã«ã«ããã·ã«ãã¢ã«ã³ãã·
ã«ã«ããã«ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåæããïŒãŸãã¯ã¢ããã«ã«ããã«ã«ããïŒ
åãŸãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒçœ®æãããŠã
ãããšãããïŒãªã©ã§ããïŒ (c) ã¢ã«ã±ã³ãªãã·ïŒççŽ ååãïŒãïŒåã奜ãŸ
ããã¯ïŒãïŒåæãããïŒè©²ã¢ã«ã±ã³ãªãã·ã¯
ããšãã«ã§ïŒåãŸãã¯æ°åïŒå¥œãŸããã¯ïŒåïŒ
眮æããããšãã§ããããŸã眮æåºã®ããšãã«
ãããããã·ã«ãC1ãC4ã¢ã«ãã«ãC1ãC4ã¢
ã«ã³ãã·ãããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ããã³è
çŽ ïŒãã«ã«ããã·ã«ãã¢ã«ã³ãã·ã«ã«ããã«
ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæããïŒ
ãŸãã¯ã¢ããã«ã«ããã«ã«ããïŒåãŸãã¯æ°å
ïŒå¥œãŸããã¯ïŒåïŒçœ®æãããŠããŠãããïŒ (d) ã¢ã«ãã³ãªãã·ïŒççŽ ååãïŒãïŒåã奜ãŸ
ããã¯ïŒãïŒåæãããïŒïŒ (e) ã·ã¯ãã¢ã«ã³ãã·ïŒççŽ ååãïŒãïŒåã奜
ãŸããã¯ïŒãïŒåæãããïŒïŒ (f) ã¢ãªãŒã«ãªãã·ïŒå¥œãŸããã¯ãããšãã«ãªã
ã·ãïŒè©²ã¢ãªãŒã«ãªãã·ã¯å Žåã«ããïŒåãŸã
ã¯æ°åïŒå¥œãŸããã¯ïŒåãŸãã¯ïŒåïŒã®çœ®æåº
ã§çœ®æããããšãã§ããã眮æåºã¯ããã²ã³
ïŒç¹ã«å¡©çŽ ããã³èçŽ ïŒãC1ãC4ã¢ã«ãã«ãã
ãããã·ã«ãC1ãC4ã¢ã«ã³ãã·ãããããã¢
ãããC1ãC4ã¢ã«ãã«ã¢ããããžã¢ã«ãã«ã¢
ããïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒãïŒåæ
ããïŒãã¹ã«ããã¢ããã«ã«ããã«ãã«ã«ãã
ã·ã«ãŸãã¯ã¢ã«ã³ãã·ã«ã«ããã«ïŒè©²ã¢ã«ãã«
éšåã¯ççŽ ååãïŒãïŒåæããïŒã§ããïŒ (g) ã¢ã©ã«ã³ãã·ïŒå¥œãŸããã¯ããšãã«ã¢ã«ã³ã
ã·ãããã§ã該ã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåã奜ãŸããã¯ïŒãïŒåæãããïŒè©²ã¢ã©ã«
ã³ãã·åºã®ã¢ãªãŒã«éšåã¯å Žåã«ããïŒåãŸã
ã¯æ°åã奜ãŸããã¯ãïŒåãŸãã¯ïŒåã®çœ®æåº
ã§çœ®æããããšãã§ããã該眮æåºã¯ããã²ã³
ïŒå¥œãŸããã¯å¡©çŽ ããã³èçŽ ïŒãC1ãC4ã¢ã«ã
ã«ãããããã·ã«ãC1ãC4ã¢ã«ã³ãã·ããã
ããã¢ãããC1ãC4ã¢ã«ãã«ã¢ããããžã¢ã«
ãã«ã¢ããïŒåã¢ã«ãã«éšåã¯ççŽ ååãïŒã
ïŒåæããïŒãã¹ã«ããã«ã«ããã·ã«ãã¢ã«ã³
ãã·ã«ã«ããã«ïŒè©²ã¢ã«ãã«éšåã¯ççŽ ååã
ïŒãïŒåæããïŒãŸãã¯ã¢ããã«ã«ããã«ã§ã
ãïŒ (h) ã¢ããïŒ (i) ã¢ã«ãã«ã¢ããïŒè©²ã¢ã«ãã«éšåã¯ççŽ åå
ãïŒãïŒåæããïŒïŒ (j) ãžã¢ã«ãã«ã¢ããïŒåã¢ã«ãã«éšåã¯ççŽ å
åãïŒãïŒåæããããŸãã該ã¢ã«ãã«éšåã¯
éç°ããŠïŒãïŒå¡ã奜ãŸããã¯ãïŒãïŒå¡ç°ã
圢æããããšãã§ãããŸãã該ç°ã¯å Žåã«ãã
å¥ã®ããçŽ ååãŸãã¯é žçŽ ååãå«æããããš
ãã§ããïŒïŒ (k) ã¢ã«ã±ãã«ã¢ããïŒè©²ã¢ã«ã±ãã«éšåã¯ççŽ
ååãïŒãïŒåã奜ãŸããã¯ãïŒãïŒåæã
ãïŒïŒ (l) ã¢ãªãŒã«ã¢ãããŸãã¯ã¢ãªãŒã«ã¡ãã«ã¢ãã
ïŒç¹ã«ãããšãã«ã¢ãããŸãã¯ãã³ãžã«ã¢ããïŒ
該ã¢ãªãŒã«éšåã¯å Žåã«ããïŒåãŸãã¯æ°å
ïŒå¥œãŸããã¯ïŒåïŒã®çœ®æåºã§çœ®æãããŠããŠ
ãããã該眮æåºã¯ããã²ã³ïŒç¹ã«å¡©çŽ ãŸãã¯
èçŽ ïŒãC1ãC4ã¢ã«ãã«ãããããã·ãC1ãC4
ã¢ã«ã³ãã·ãããããã¢ãããC1ãC4ã¢ã«ã
ã«ã«ããããžã¢ã«ãã«ã¢ããïŒåã¢ã«ãã«éšå
ã¯ççŽ ååãïŒãïŒåæããïŒããŸãã¯ã¢ãã
ã«ã«ããã«ã§ããïŒ ãªã©ã§ããã æ¬çºæã«ãšã€ãŠç¹ã«å¥œãŸããR3ã®åºãäžèšã«
ãããã R3ãççŽ ååãïŒãïŒåæããå Žåã«ãã眮
æãããŠããããšãããã¢ã«ã³ãã·åºã瀺ãå Ž
åãå ·äœäŸãšããŠã¯ã¡ããã·ããšããã·ãããã
ãã·ãã€ãœããããã·ããããã·ãã€ãœããã
ã·ãïœâãããã·ãã¡ããã·ãšããã·ããšããã·
ãšããã·ãã¡ããã·ãšããã·ãšããã·ãã¡ããã·
ãšããã·ãšããã·ãšããã·ããšããã·ãšããã·ãš
ããã·ãšããã·ãããšããã·ãšããã·ãïŒâã¯ã
ãããšããã·ãšããã·ãïŒâã¡ãã«ããšããã·ãš
ããã·ããã³ïŒâã¡ããã·ããšããã·ãšããã·ãª
ã©ãããããããã¡ããã·ããšããã·ãã€ãœãã
ããã·ãã€ãœãããã·ãïœâãããã·ãã¡ããã·
ãšããã·ãã¡ããã·ãšããã·ãšããã·ãããšãã
ã·ãšããã·ããã³ïŒâã¯ããããšããã·ãç¹ã«å¥œ
ãŸããã R3ãå Žåã«ãã眮æãããŠããããšãããã¢
ã«ã±ã³ãªãã·ã瀺ãå Žåãå ·äœäŸãšããŠã¯ã¢ãªã«
ãªãã·ããã³ã·ã³ããã«ãªãã·ãç¹ã«å¥œãŸããåº
ãšããŠãããããã R3ãã¢ã«ãã³ãªãã·ã§ããå Žåãç¹ã«å¥œãŸã
ããã®ã¯ãããã«ã®ã«ãªãã·ã§ããã R3ãã·ã¯ãã¢ã«ã³ãã·ã§ããå Žåãããã¯äŸ
ãã°ãã·ã¯ãããããã·ãã·ã¯ããããã·ãã·ã¯
ããã³ãã«ãªãã·ãŸãã¯ã·ã¯ãããã·ã«ãªãã·ãª
ã©ã§ãããã·ã¯ããã³ãã«ãªãã·ããã³ã·ã¯ãã
ãã·ã«ãªãã·ãç¹ã«å¥œãŸããã R3ãã¢ãªãŒã«ãªãã·ã瀺ãå ŽåãR3ã¯ããšã
ãã·ãïŒâããªã«ãªãã·ãïŒâã¯ããããã³ïŒâ
ã¯ããããšããã·ãïŒïŒïŒâãžã¯ããããšãã
ã·ãïŒâããããã·ããã³ïŒâããããã·ããšã
ãã·ãïŒïŒïŒâãžããããã·ããšããã·ãïŒâã¡
ããã·ããšããã·ãïŒïŒïŒâãžã¡ããã·ããšãã
ã·ãïŒâãããããšããã·ãïŒâãããããšãã
ã·ãïŒâã¢ããããšããã·ãïŒâãžã¡ãã«ã¢ãã
ããšããã·ãïŒâãžãšãã«ã¢ããããšããã·ãïŒ
âã¹ã«ãããšããã·ãïŒâã«ã«ããã·ããšãã
ã·ãïŒâã«ã«ããã·ããšããã·ãïŒâãšããã·ã«
ã«ããã«ããšããã·ããã³ïŒâã¢ããã«ã«ããã«
ããšããã·ãªã©ã§ãããããšããã·ãïŒâã¯ãã
ããšããã·ãïŒïŒïŒâãžã¯ããããšããã·ãïŒâ
ã¡ããã·ããšããã·ãïŒïŒïŒâãžã¡ããã·ããšã
ãã·ãããã³ïŒâãžã¡ãã«ã¢ãããã·ãç¹ã«å¥œãŸ
ããã R3ãã¢ã©ã«ã³ãã·ã瀺ãå ŽåãäŸãã°ããã³
ãžã«ãªãã·ãïŒâã¡ãã«ãã³ãžã«ãªãã·ãïŒâã¯
ãããã³ãžã«ãªãã·ãïŒâã¡ããã·ãã³ãžã«ãªã
ã·ãïŒïŒïŒâãžã¡ããã·ãã³ãžã«ãªãã·ãïŒâã
ãããã·ãã³ãžã«ãªãã·ãïŒâããããã³ãžã«ãª
ãã·ãïŒâã«ã«ããã·ãã³ãžã«ãªãã·ãïŒâã«ã«
ããã·ãã³ãžã«ãªãã·ãïŒâãšããã·ã«ã«ããã«
ãã³ãžã«ãªãã·ãïŒâã¢ããã«ã«ããã«ãã³ãžã«
ãªãã·ãïŒâãžã¡ãã«ã¢ãããã³ãžã«ãªãã·ãã
ã³ããšãããã·ãªã©ããããããã奜ãŸããåºã¯
ãã³ãžã«ãªãã·ãïŒâã¯ãããã³ãžã«ãªãã·ã
ïŒïŒïŒâãžã¯ãããã³ãžã«ãªãã·ãïŒâã¡ããã·
ãã³ãžã«ãªãã·ãïŒïŒïŒâãžã¡ããã·ãã³ãžã«ãª
ãã·ãïŒâã«ã«ããã·ãã³ãžã«ãªãã·ãïŒâã¢ã
ããã³ãžã«ãªãã·ããã³ïŒâãžã¡ãã«ã¢ãããã³
ãžã«ãªãã·ã§ããã R3ãã¢ã«ãã«ã¢ããã§ããå Žåãããã¯äŸã
ã°ãã¡ãã«ã¢ããããšãã«ã¢ããããããã«ã¢ã
ããŸãã¯ããã«ã¢ããã瀺ãããšãã§ããã奜ãŸ
ããã¯ã¡ãã«ã¢ããããã³ãšãã«ã¢ããã瀺ãã R3ããžã¢ã«ãã«ã¢ããã瀺ãå Žåãããã¯äŸ
ãã°ããžã¡ãã«ã¢ããããžãšãã«ã¢ããããžãã
ãã«ã¢ããããžã€ãœãããã«ã¢ãããïŒâãããª
ãžã«ãïŒâãããªãžãã«ãïŒâããã©ãžãã«ãïŒ
âãšãã«âïŒâããã©ãžãã«ãããã³ïŒâã¢ã«ã
ãªãã«ãªã©ã§ããã奜ãŸããã¯ããžã¡ãã«ã¢ã
ãããžãšãã«ã¢ãããïŒâãããªãžã«ãïŒâãã
ãªãžãã«ããã³ïŒâã¢ã«ããªãã«ã§ããã R3ãã¢ã«ã±ãã«ã¢ããã瀺ãå Žåãå ·äœäŸãš
ããŠãã¢ãªã«ã¢ããããããããã R3ãã¢ãªãŒã«ã¢ããã§ããå Žåãå ·äœäŸã«ã¯ã
ã¢ããªããïŒâããªã«ã¢ãããïŒâã¯ããããšã
ã«ã¢ãããïŒâããããã·ããšãã«ã¢ãããïŒâ
ã¡ããã·ããšãã«ã¢ãããïŒâã¡ããã·ããšãã«
ã¢ãããïŒâãããããšãã«ã¢ãããïŒâã¢ãã
ããšãã«ã¢ãããïŒâã¡ãã«ã¢ããããšãã«ã¢ã
ããïŒâãžã¡ãã«ã¢ããããšãã«ã¢ãããïŒâã¹
ã«ãããšãã«ã¢ãããïŒâã«ã«ããã·ããšãã«ã¢
ãããïŒâã«ã«ããã·ããšãã«ã¢ãããïŒâãšã
ãã·ã«ã«ããã«ããšãã«ã¢ãããããã³ïŒâã¢ã
ãã«ã«ããã«ããšãã«ã¢ãããªã©ããããããã
奜ãŸããåºã¯ã¢ããªããïŒâã¯ããããšãã«ã¢ã
ããïŒâã¡ããã·ããšãã«ã¢ãããïŒâã«ã«ãã
ã·ããšãã«ã¢ãããããã³ïŒâã¢ããã«ã«ããã«
ããšãã«ã¢ããã§ããã察å¿ãã眮æåºã¯ã¢ãªãŒ
ã«âCH2âã¢ããåºã«ã奜é©ã§ããã æ¬çºæã«ãããŠäœ¿çšããã®ã«ç¹ã«å¥œãŸããåå
ç©ã¯ã»ããªãžãžã ïŒcefodizimïŒã§ãããããã¯
åŒäžã®R1ãã¡ãã«ã§ãããR2ãNaã瀺ãããã
ãŠR3ãONaã瀺ãäžè¬åŒã®ååç©ã«çžåœããã äžè¬åŒã®ååç©ããã³ãã®è£œé æ¹æ³ã¯äŸã
ã°ã西ç¬ç¹èš±å ¬éå ¬å ±ç¬¬2716707å·ãå第3117438
å·ããã³å第3143537å·ã«é瀺ãããŠããã çç©ãäœæ¶²ããã³çŽ°èå ç«é²åŸ¡æ©æ§ãæããã
ãšã¯å ¬ç¥ã§ããããã®å ç«é²åŸ¡æ©æ§ã¯ãäœå ã«æµž
å ¥ãããããŠçºç å€åãèµ·ããããšã®ããç°ç©ã
äžåããã³é€å»ãããå ç«ç³»ã®é害ã«ãšããªã
ãããŸãã¯ãäŸãã°åŸ®çç©ãŸãã¯ç现èã®ãããª
ç åäœãæ±ãå ç«æ©èœã®äžå šã«èµ·å ããæ§ã ãªçŸ
æ£ãããããã®ãããæã ã¯çäœã®é²åŸ¡æ©æ§ãæ¯
æŽããã®ã«åºç¯ã«äœ¿çšã§ããé«å¹çã§é«èš±å®¹æ§ã®
å ç«èª¿æŽç©è³ªãé·å¹Žã«ããããããæ±ããŠããã æ¬çºæã®ç®çã¯ãå ç«è¬çåŠç掻æ§ãæããç§
åŠçã«ç»å®ãããäœæ¯æ§ã§ãããããå±æããã³
å šèº«æ§çŽ°èææã®æ²»ççšã®çŸçšæçç©è³ªã§ããæ°
ããã¿ã€ãã®ç©è³ªãæäŸããããšã§ãããäŸã
ã°ãã¯ãã©ã ããšãã³ãŒã«ãŸãã¯ããã©ãµã€ã¯ãª
ã³ã®ãããªããããæèäœçšãæããå€ãã®åå
ç©ã¯çäœã®é²åŸ¡æ©æ§ã«å¯ŸããŠå¯äœçšãæããããš
ãç¥ãããŠãããåŸã€ãŠãæ¬çºæã«ããååç©ã
äœæ¿åºŠã§å ç«å¿çã«å¯ŸããŠæçãªå¹æãæããã
å³ã¡ããã®ãããªååç©ã¯æ害ãªå¯äœçšãªãã«å
ç«å¿çæ§ãé«ããããšãã§ããããšããããšã¯ã
ã©ããã¹ãããšã§ãã€ãã åŸã€ãŠãæ¬çºæã®æ°èŠååç©ã¯åºç¯å²ã¹ãã¯ã
ã«ã®æçç©è³ªãšããŠå¥œé©ã§ããã°ããã§ãªããã
ã®å ç«åºæ¿äœçšã«ãã第ïŒã®éèŠãªæ©èœãçºæ®ã
ãããã®ããšã¯çãŸãã€ãããŸãã¯å 倩çã«äœè
æ§ã®æ£è ãéŠå°Ÿããå埩ãããã®ã«æ¥µããŠéèŠã§
ãããæŽã«ãæ¬çºæã®æ°èŠååç©ã¯ææçã®äºé²
ãŸãã¯åŸ®çç©ã®é€å»ãããã¯çäœãã现èãå€æ§
ãããããã«ã䜿çšã§ãããäŸãã°ãåç©è©Šéšã«
ãããŠãã»ããªãžãžã ãäºé²æäžããããšã«ãã€
ãŠããŠã¹ã®èŽæ»æ§ã®ã«ã³ãžãææçã«å¯Ÿãã芳å¯
æéã®æçµæ¥ïŒ14æ¥ç®ïŒã§65ïŒ ä»¥äžã®çåçãåŸ
ããããšããç»æçå¹æã確èªããããåã芳å¯
æéã«ã€ããŠè¡ãªãããå¯Ÿç §çŸ€ã§ã¯å¯ã®äžå¹ã®ã
ãŠã¹ãçåããªãã€ãã æ¬çºæã«ããã°ã掻æ§æåã¯éçµå£ããã³çµå£
ã®ãããã®çµè·¯ã«ãã€ãŠãæäžã§ããã å ç«èª¿ç¯äœçšãæããæäžéã¯ãéçµå£æäžã®
å ŽåãäœéïŒKgãããïŒã200mgã奜ãŸããã¯10
ã50mgã®ç¯å²å ã§ããã掻æ§æåã¯åç¬ã§æäžã
ãããšãã§ãããããããã¯ãææçããã³çè «
çã«å¯ŸããŠææãªå¹æãæãããã®ä»ã®è¬å€ãšäœµ
çšããŠæäžããããšãã§ããã氎溶液ã®è£œå€ã®å Ž
åã掻æ§æåã¯å¥œãŸããã¯ãäŸãã°åèšã®R2ã®
å®çŸ©ããæãããªããã«ã氎溶æ§ã§ãããããç
çåŠçã«å容ãããå¡©ã®åœ¢ã§äœ¿çšãããåŠæ¹ã«ã¯
åžžçšã®å©å€ããã³ããã¯ã«ãé åã§ããããã®ã
ããªå©å€ããã³ããã¯ã«ãšããŠå¥œé©ãªãã®ã¯äŸã
ã°å¢éå€ãä¹³åå€ãæ»æ²¢å€ãããã³ç·©è¡åå€ã§ã
ãã掻æ§æåã¯éé¢é žãŸãã¯å¡©ãšããŠè£œå€çšå©å€
ãšæ··åããããéé¢é žã®åœ¢ã§æ··åããå Žåãé©åœ
ãªå¡©åºãçéã ãå©å€ã«æ·»å ãã¹ãã§ãããã掻
æ§æåãæžæ¿æ¶²ã®åœ¢ã§äœ¿çšãããå Žåã補å€çšã«
䜿çšã§ãã奜é©ãªããã¯ã«ã¯äŸãã°æ€ç©æ²¹ã®ãã
ãªããããã·ã«åºãå«æããªã溶å€ã§ããã äžèšã«ç€ºãããå®éšçµæã¯äžè¬åŒã®ååç©ã®
å ç«èª¿ç¯äœçšãäŸèšŒãããã®ã§ãããå ç«èª¿ç¯äœ
çšãè©äŸ¡ããã®ã«å¥œé©ã§ããããšãç¥ãããŠãã
æ§ã ãªè©Šéšæ¹æ³ã䜿çšããã å®æœäŸ ïŒ ããŠã¹ã®è ¹èãã¯ããã¢ãŒãžã®åºæ¿ ãã¯ããã¢ãŒãžã¯ææçã«å¯Ÿããæµæããã³å
ç«å¿çã«ãããŠäžå¿ç圹å²ãæŒãããäžæ¹ã§ã¯ã
ãã¯ããã¢ãŒãžèªäœãç åäœãæé€ããä»æ¹ã§
ã¯ããã¯ããã¢ãŒãžã¯äœæ¶²ïŒïŒ¢â现èäŸåæ§ïŒå
ç«å¿çããã³çŽ°èïŒïŒŽâ现èäŸåæ§ïŒå ç«å¿çã®
調ç¯ã«ãããã³ã³ãããŒã«æ©èœãæããã ã»ããªãžãžã ã7.5ã60mgïŒKgïŒããŠã¹ïŒã®é
ã®æ§ã ãªæ¿åºŠã§NMRIããŠã¹ã«é泚ïŒïŒåïŒã
ããè¬å€ãæäžããŠãã72æéåŸãè ¹èãã¯ãã
ã¢ãŒãžãåé¢ãããããŠãåæ©èœã«ã€ããŠè©Šéšã
ããå¯Ÿç §çŸ€ããåé¢ãããã¯ããã¢ãŒãžãšæ¯èŒã
ããšãã»ããªãžãžã ïŒ15ã60mgïŒKgïŒããŠã¹ïŒïŒ
ã§åŠçããããŠã¹ããåé¢ãããã¯ããã¢ãŒãžã®
ååŠã«ãããã»ã³ã¹åå¿ã¯æäžéã®å¢å ã«ã€ããŠ
èããå¢å€§ããïŒè¡šïŒïŒã ã»ããªãžãžã ïŒåŒãåŒäžR1ïŒCH3ïŒR2ïŒ
NaïŒR3ïŒONaïŒã§åŠçããããŠã¹ããåé¢ãã
ãã¯ããã¢ãŒãžã¯ãªãœãœãŒã é µçŽ ã®å«éãå¢å€§ã
ãããšã«ãã€ãŠãåºå¥ãããã ã»ããªãžãžã ã§åŠçãããããŠã¹ããåé¢ãã
ãã¯ããã¢ãŒãžã«ããã³ãã€ãç¶éïŒ198AuïŒã®
飲äœçšã¯éåŠçããŠã¹ããåé¢ãããã¯ããã¢ãŒ
ãžã«æ¯ã¹ãŠãé¡èã«å¢å€§ããïŒå¯Ÿç §çŸ€ã§ã¯0.207
Ã103cpmãªã®ã«å¯ŸããŠã»ããªãžãžã ã§åŠçãã
ããŠã¹ããåé¢ãããã¯ããã¢ãŒãžã§ã¯0.43Ã
103ïŒã
ãè¡šã
å®æœäŸ ïŒ
é
延åã®å
ç«åŠçå¿çïŒé
延åéæçãDTHïŒ
ã®å¢åŒ·äœçš ãã®è©Šéšã¯å ç«åœ¢ã®ïŒŽâ现èäŸåæåã®æ©èœå
ã調ã¹ããã®ã§ãããNMRIããŠã¹ã«æ§ã ãªæ¿
床ã®ã»ããªãžãžã ãæ°åè ¹è å æäžããããšã«ã
ãäºååŠçãããæåŸã®æ¥ã«çæç©ãæäžããã
ããžã®è¡æ¶²ããæ¡åããèµ€è¡çãé泚ããããšã«
ããå šãŠã®ããŠã¹ãå ç«åãããæŽã«ïŒæ¥éçµé
ããåŸããããžã®è¡æ¶²ããæ¡åããèµ€è¡çã足åº
å ã«æäžããéã®DTHå¿çã枬å®ããã ã»ããªãžãžã ã§äºååŠçãããããŠã¹ã¯å¯Ÿå¿ã
ãå¯Ÿç §çŸ€ã®ããŠã¹ã®å¿çãããã¯ããã«é¡èãª
DTHå¿çã瀺ãã«ã¯æããã§ããïŒè¡šïŒåç §ïŒã
ã®å¢åŒ·äœçš ãã®è©Šéšã¯å ç«åœ¢ã®ïŒŽâ现èäŸåæåã®æ©èœå
ã調ã¹ããã®ã§ãããNMRIããŠã¹ã«æ§ã ãªæ¿
床ã®ã»ããªãžãžã ãæ°åè ¹è å æäžããããšã«ã
ãäºååŠçãããæåŸã®æ¥ã«çæç©ãæäžããã
ããžã®è¡æ¶²ããæ¡åããèµ€è¡çãé泚ããããšã«
ããå šãŠã®ããŠã¹ãå ç«åãããæŽã«ïŒæ¥éçµé
ããåŸããããžã®è¡æ¶²ããæ¡åããèµ€è¡çã足åº
å ã«æäžããéã®DTHå¿çã枬å®ããã ã»ããªãžãžã ã§äºååŠçãããããŠã¹ã¯å¯Ÿå¿ã
ãå¯Ÿç §çŸ€ã®ããŠã¹ã®å¿çãããã¯ããã«é¡èãª
DTHå¿çã瀺ãã«ã¯æããã§ããïŒè¡šïŒåç §ïŒã
ãè¡šã
ãã®çµæã¯ã»ããªãžãžã ã®äºé²æäžãããŠã¹ã®
â现èç³»ã«å¯Ÿãåºæ¿å¹æãæããããšã瀺ããŠ
ããã å®æœäŸ ïŒ BaIbïŒïŒ£ããŠã¹ã®éµå£ç¡ã«ã³ãžãèææã«å¯Ÿ
ããæµææ§ã®å¢å€§ BaIbïŒïŒ£ããŠã¹ã«ã»ããªãžãžã ãïŒÃ30mgïŒ
KgïŒæ¥ã®æäžéã§ïŒæ¥éè ¹è å æäžãããã»ããª
ãžãžã ã®æåŸã®æäžãã24æéçµéåŸã«ãã»ããª
ãžãžã æäžããŠã¹ããã³å¯Ÿç §çŸ€ããŠã¹ïŒãããã«
ã¯åãéã®ççé£å¡©æ°Žãåãæäžåæ°ããã³æäž
æéã«ããã€ãŠæäžããïŒã«éµå£ç¡ã«ã³ãžãè
ïŒïŒÃ106CFUïŒããŠã¹ïŒãé泚ããææãããã
å¯Ÿç §çŸ€ã®ããŠã¹ã¯å¹³å3.5æ¥éçµéåŸã«æ»äº¡ãã
ãããŠãé·ããŠãããããïŒæ¥éçµéåŸã«ã¯å šãŠ
ã®å¯Ÿç §ããŠã¹ãæ»äº¡ãããã»ããªãžãžã ã§åŠçã
ããããŠã¹ã¯èŠ³å¯æéã®14æ¥çµéåŸã65ïŒ ä»¥äžã
çåããŠããããã®ææè©Šéšã®çµæã¯ã»ããªãžãž
ã ã®äºé²æäžã«ããBaIbïŒïŒ£ããŠã¹ã®éµå£ç¡ã«
ã³ãžãèã«ããææã«å¯Ÿããæµææ§ãå¢å€§ããã
ãšã瀺ããŠããã å®æœäŸ ïŒ ã»ããªãžãžã ã®æ§ã ãªèªå°äœã«ããDTHå¿ç
ããã³ãã¯ããã¢ãŒãžæŽ»æ§ã®åºæ¿ å®æœäŸïŒããã³ïŒã«æ¢ã«è¿°ã¹ãããã«ã
NMRIããŠã¹ã«æ§ã ãªæ¿åºŠïŒ10ã200mgïŒKgïŒã®
ã»ããªãžãžã ãéçµå£æäžããããšã«ããåŠçã
ããæ¯èŒã®ããã«ãäžèšã®çœ®æåºãæããäžè¬åŒ
ã®ååç©ãå¥ã®ããŠã¹ã«æäžããã
â现èç³»ã«å¯Ÿãåºæ¿å¹æãæããããšã瀺ããŠ
ããã å®æœäŸ ïŒ BaIbïŒïŒ£ããŠã¹ã®éµå£ç¡ã«ã³ãžãèææã«å¯Ÿ
ããæµææ§ã®å¢å€§ BaIbïŒïŒ£ããŠã¹ã«ã»ããªãžãžã ãïŒÃ30mgïŒ
KgïŒæ¥ã®æäžéã§ïŒæ¥éè ¹è å æäžãããã»ããª
ãžãžã ã®æåŸã®æäžãã24æéçµéåŸã«ãã»ããª
ãžãžã æäžããŠã¹ããã³å¯Ÿç §çŸ€ããŠã¹ïŒãããã«
ã¯åãéã®ççé£å¡©æ°Žãåãæäžåæ°ããã³æäž
æéã«ããã€ãŠæäžããïŒã«éµå£ç¡ã«ã³ãžãè
ïŒïŒÃ106CFUïŒããŠã¹ïŒãé泚ããææãããã
å¯Ÿç §çŸ€ã®ããŠã¹ã¯å¹³å3.5æ¥éçµéåŸã«æ»äº¡ãã
ãããŠãé·ããŠãããããïŒæ¥éçµéåŸã«ã¯å šãŠ
ã®å¯Ÿç §ããŠã¹ãæ»äº¡ãããã»ããªãžãžã ã§åŠçã
ããããŠã¹ã¯èŠ³å¯æéã®14æ¥çµéåŸã65ïŒ ä»¥äžã
çåããŠããããã®ææè©Šéšã®çµæã¯ã»ããªãžãž
ã ã®äºé²æäžã«ããBaIbïŒïŒ£ããŠã¹ã®éµå£ç¡ã«
ã³ãžãèã«ããææã«å¯Ÿããæµææ§ãå¢å€§ããã
ãšã瀺ããŠããã å®æœäŸ ïŒ ã»ããªãžãžã ã®æ§ã ãªèªå°äœã«ããDTHå¿ç
ããã³ãã¯ããã¢ãŒãžæŽ»æ§ã®åºæ¿ å®æœäŸïŒããã³ïŒã«æ¢ã«è¿°ã¹ãããã«ã
NMRIããŠã¹ã«æ§ã ãªæ¿åºŠïŒ10ã200mgïŒKgïŒã®
ã»ããªãžãžã ãéçµå£æäžããããšã«ããåŠçã
ããæ¯èŒã®ããã«ãäžèšã®çœ®æåºãæããäžè¬åŒ
ã®ååç©ãå¥ã®ããŠã¹ã«æäžããã
ãè¡šã
ãã¯ããã¢ãŒãžäœçšïŒååŠã«ãããã»ã³ã¹ãã
ã³é µçŽ 掻æ§ïŒããã³DTHå¿çãå ç«åºæ¿æ€åºè©Š
éšæ³ã«ããè©äŸ¡ããã äžèšã®è¡šïŒã¯ã»ããªãžãžã ã«å¯Ÿããåååç©ã®
çžå¯Ÿå¹åã瀺ãã100ïŒ ã®æ°å€ã¯è¡šïŒããã³è¡šïŒ
ã«ç€ºããããããªã»ããªãžãžã ã«ããæ倧掻æ§
ïŒå¯Ÿç §å€ãšåºæ¿å€ãšã®å·®ïŒã«çžåœããã
ã³é µçŽ 掻æ§ïŒããã³DTHå¿çãå ç«åºæ¿æ€åºè©Š
éšæ³ã«ããè©äŸ¡ããã äžèšã®è¡šïŒã¯ã»ããªãžãžã ã«å¯Ÿããåååç©ã®
çžå¯Ÿå¹åã瀺ãã100ïŒ ã®æ°å€ã¯è¡šïŒããã³è¡šïŒ
ã«ç€ºããããããªã»ããªãžãžã ã«ããæ倧掻æ§
ïŒå¯Ÿç §å€ãšåºæ¿å€ãšã®å·®ïŒã«çžåœããã
ãè¡šã
ãã®è¡šããæãããªããã«ãéåŠçããŠã¹ãã
åŸããããã¯ããã¢ãŒãžã«æ¯ã¹ãŠãæ¢ã«ã»ããªãž
ãžã ã«ã€ããŠç€ºãããããã«ãåèšã®å šãŠã®èªå°
äœã«ãããåŠçãã¯ããã¢ãŒãžã®ååŠã«ãããã»
ã³ã¹åå¿ã¯èããåºæ¿ããããããããã®ãªãœãœ
ãŒã é µçŽ ã®å«éã¯é£èºçã«å¢å€§ãããæŽã«ãã»ã
ãªãžãžã èªå°äœã§äºååŠçãããããŠã¹ã®DTH
å¿çã¯å¯Ÿå¿ããå¯Ÿç §çŸ€ã®ããŠã¹ãããã¯ããã«æ
確ã§ãã€ãã
åŸããããã¯ããã¢ãŒãžã«æ¯ã¹ãŠãæ¢ã«ã»ããªãž
ãžã ã«ã€ããŠç€ºãããããã«ãåèšã®å šãŠã®èªå°
äœã«ãããåŠçãã¯ããã¢ãŒãžã®ååŠã«ãããã»
ã³ã¹åå¿ã¯èããåºæ¿ããããããããã®ãªãœãœ
ãŒã é µçŽ ã®å«éã¯é£èºçã«å¢å€§ãããæŽã«ãã»ã
ãªãžãžã èªå°äœã§äºååŠçãããããŠã¹ã®DTH
å¿çã¯å¯Ÿå¿ããå¯Ÿç §çŸ€ã®ããŠã¹ãããã¯ããã«æ
確ã§ãã€ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æ¬¡åŒã§ç€ºãããã»ããšã ååç©ãæå¹éå«
æããããšãç¹åŸŽãšããåºä¹³é¡ã®å ç«å¿çæ§ãé«
ããçµæç©ã ãåã ãåŒäžãR1ã¯æ°ŽçŽ ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ã«ãã«ãã«ã«ããã·ã¡ãã«ïŒãã
ã§ã該ã«ã«ããã·ã«åºã¯ççåŠçã«å容ã§ããå¡©
ãŸãã¯ççåŠçã«å容ã§ãããšã¹ãã«ã®åœ¢ãããŠ
ããŠãããïŒãã¢ã«ã³ãã·ã«ã«ããã«ã¡ãã«ãã¢
ããã«ã«ããã«ã¡ãã«ãŸãã¯ã·ã¢ãã¡ãã«ã§ã
ãããŸãããããã®åºäžã®ã¡ãã¬ã³åºã¯å Žåã«ã
ã眮æãããŠããŠãããïŒ R2ã¯æ°ŽçŽ ãççåŠçã«å容ã§ããã«ããªã³ãŸ
ãã¯ççåŠçã«å容ã§ãããšã¹ãã«åºã§ããïŒ R3ã¯ããããã·ã«ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠ
ããããšãããã¢ã«ã±ã³ãªãã·ãã¢ã«ãã³ãªã
ã·ãã·ã¯ãã¢ã«ã³ãã·ãå Žåã«ãã眮æãããŠã
ãããšãããã¢ãªãŒã«ãªãã·ãå Žåã«ãã眮æã
ããŠããããšãããã¢ã©ã«ã³ãã·ãã¢ãããã¢ã«
ãã«ã¢ããããžã¢ã«ãã«ã¢ããïŒããã§ããã®äº
åã®ã¢ã«ãã«åºã¯éç°ããŠïŒãïŒå¡ç°ã圢æãã
ããšãã§ãã該ç°ã¯ãŸãå Žåã«ããå¥ã®ããçŽ ãŸ
ãã¯é žçŽ ååãå«æããŠããŠãããïŒãã¢ã«ã±ã
ã«ã¢ããããŸãã¯å Žåã«ãã眮æãããŠããããš
ãããã¢ãªãŒã«ã¢ããè¥ããã¯ã¢ãªãŒã«âCH2â
ã¢ããã§ããïŒ R1åºã¯ã·ã³äœçœ®ã«é 眮ããŠãããã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843405728 DE3405728A1 (de) | 1984-02-17 | 1984-02-17 | Verwendung von cephemverbindungen als immunmodulatoren |
| DE3405728.5 | 1984-02-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60193921A JPS60193921A (ja) | 1985-10-02 |
| JPH0570604B2 true JPH0570604B2 (ja) | 1993-10-05 |
Family
ID=6228021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60028142A Granted JPS60193921A (ja) | 1984-02-17 | 1985-02-15 | åºä¹³é¡ã®å ç«å¿çæ§ãé«ããçµæç© |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4701452A (ja) |
| EP (1) | EP0152860B1 (ja) |
| JP (1) | JPS60193921A (ja) |
| AT (1) | ATE43966T1 (ja) |
| AU (1) | AU581206B2 (ja) |
| CA (1) | CA1240926A (ja) |
| DE (2) | DE3405728A1 (ja) |
| ZA (1) | ZA851157B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3923541A1 (de) * | 1989-07-15 | 1991-01-24 | Hoechst Ag | Cephalosporinderivate und verfahren zu ihrer herstellung |
| TW252112B (ja) * | 1993-08-19 | 1995-07-21 | Pfizer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714880A1 (de) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| DE3117438A1 (de) * | 1981-05-02 | 1982-11-18 | Hoechst Ag, 6000 Frankfurt | Cephemderivate und verfahren zu ihrer herstellung |
| US4387124A (en) * | 1981-10-29 | 1983-06-07 | International Business Machines Corporation | Coating apparatus and method |
| DE3143537A1 (de) * | 1981-11-03 | 1983-05-11 | Hoechst Ag, 6230 Frankfurt | Kristalline salze von cefodizim und verfahren zu ihrer herstellung |
| AU553252B2 (en) * | 1982-11-01 | 1986-07-10 | Sanofi-Aventis Deutschland Gmbh | Crystalline salts of cefodizim |
-
1984
- 1984-02-17 DE DE19843405728 patent/DE3405728A1/de not_active Withdrawn
-
1985
- 1985-02-06 EP EP85101220A patent/EP0152860B1/de not_active Expired
- 1985-02-06 AT AT85101220T patent/ATE43966T1/de not_active IP Right Cessation
- 1985-02-06 DE DE8585101220T patent/DE3570980D1/de not_active Expired
- 1985-02-15 CA CA000474485A patent/CA1240926A/en not_active Expired
- 1985-02-15 JP JP60028142A patent/JPS60193921A/ja active Granted
- 1985-02-15 US US06/702,319 patent/US4701452A/en not_active Expired - Fee Related
- 1985-02-15 ZA ZA851157A patent/ZA851157B/xx unknown
- 1985-02-15 AU AU38784/85A patent/AU581206B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ATE43966T1 (de) | 1989-06-15 |
| EP0152860B1 (de) | 1989-06-14 |
| ZA851157B (en) | 1985-09-25 |
| US4701452A (en) | 1987-10-20 |
| DE3570980D1 (en) | 1989-07-20 |
| EP0152860A3 (en) | 1986-07-09 |
| AU581206B2 (en) | 1989-02-16 |
| AU3878485A (en) | 1985-08-22 |
| EP0152860A2 (de) | 1985-08-28 |
| CA1240926A (en) | 1988-08-23 |
| DE3405728A1 (de) | 1985-08-22 |
| JPS60193921A (ja) | 1985-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5945420A (en) | Immunopotentiating and infection protective agent and production thereof | |
| CA2135474A1 (en) | Thiazolidine Derivatives and Pharmaceutical Compositions Containing the Same | |
| FR2631828A1 (fr) | Utilisation d'une substance folinique en tant qu'agent antiagregant plaquettaire | |
| EP1641460B1 (de) | Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat | |
| US20030035812A1 (en) | Immune enhancement compositions and use thereof | |
| JP5770181B2 (ja) | æçµæ žå€ãšããŠã®ã¹ãã¯ããããé¡ | |
| EP1857442A3 (en) | Novel antimycobacterial compounds | |
| CA2031886A1 (fr) | Application therapeutique des derives des fluoroquinolones | |
| JPH0570604B2 (ja) | ||
| JPS6041656A (ja) | æ°èŠã¢ããé žèªå°äœã®è£œæ³ | |
| US6399607B1 (en) | Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin | |
| JPH05201864A (ja) | å ç«è³ŠæŽ»ã»ææé²åŸ¡å€åã³ãã®è£œé æ¹æ³ | |
| JPS6354686B2 (ja) | ||
| US10576088B2 (en) | Compositions comprising finafloxacin and Tris | |
| JPH11199486A (ja) | ãã¿ãã³ïœïŒå«æå»è¬çµæç© | |
| CA2180732A1 (en) | Anti-hiv drugs | |
| KR950008483A (ko) | íŽë늰 íí©ë¬Œ | |
| WO2024224326A1 (en) | Liquid parenteral formulations of bilastine | |
| US20090298895A1 (en) | Use of thioproline in body weight reduction treatments | |
| IL37889A (en) | Indulamin inhibitors - N - methyl transferase | |
| Wolinsky et al. | Antituberculous activity of hinconstarch, a synthetic polymer of isoniazid, amithiozone, and starch | |
| BE568046A (ja) | ||
| JPS5840531B2 (ja) | æã³ã¯ã·ãžãŠã å€ | |
| IE913969A1 (en) | Novel treatment | |
| JP2007191417A (ja) | å»è¬çšã®çµæç© |